NCT02733068View on ClinicalTrials.gov

A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.

PHASE3CompletedINTERVENTIONAL

Enrollment

12,000

Participants

Timeline

Start Date

November 2, 2014

Primary Completion Date

July 30, 2019

Study Completion Date

January 16, 2020

Conditions

Human Papilloma Virus Infection Type 16Human Papilloma Virus Infection Type 18Cervical Intraepithelial Neoplasia

Interventions

BIOLOGICAL

HPV-16/18 vaccine

0.5ml of recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast) on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).

BIOLOGICAL

HPV-16/18 placebo

0.5ml of placebo on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).

All Listed Sponsors

collaborator

Guangxi Center for Disease Control and Prevention

OTHER_GOV

lead

Shanghai Zerun Biotechnology Co.,Ltd

INDUSTRY

NCT02733068 - A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine. | Biotech Hunter | Biotech Hunter